AI filing briefs · archive

8-K filings in March 2026, explained

815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 815 briefs match

newest first · times in ET

AGOASSURED GUARANTY LTD Mar 23, 5:05 PM ET

Assured Guaranty Re unit's 2025 net income rose to $124.6 million from $98.5 million

Positive earnings Written later 2.02

Assured Guaranty Ltd. furnished audited December 31, 2025 financial statements for its subsidiary Assured Guaranty Re Ltd., with a second set for Assured Guaranty Re Overseas Ltd. attached as Exhibit 99.2. The subsidiary's 2025 net income and total revenues both rose from 2024, and it paid $80.0 million in dividends, down from $97.4 million. These are subsidiary-level figures, not the parent's consolidated results.

Net income for the year ended December 31, 2025 was $124.6 million, versus $98.5 million in 2024.
Total revenues were $198.1 million in 2025, versus $163.3 million in 2024.
Dividends were $80.0 million in 2025, down from $97.4 million in 2024.
Total shareholder's equity was $1.17 billion at December 31, 2025, versus $1.09 billion a year earlier.

Read the filing on SEC.gov ↗

STROSUTRO BIOPHARMA, INC. Mar 23, 4:32 PM ET

Sutro Biopharma reports 2025 revenue of $102.5 million, net loss of $191.1 million

Mixed earnings Written later 1.02 2.02

Sutro Biopharma reported full-year 2025 results in a press release furnished with an 8-K on March 23, 2026. Revenue rose to $102.5 million from $62.0 million and net loss narrowed to $191.1 million from $227.5 million, but the company also recorded $53.4 million in restructuring and related costs. The company also terminated its at-the-market share sales agreement with Jefferies LLC effective March 23, 2026, so it can no longer sell common shares under that program.

Revenue was $102.5 million for 2025, up from $62.0 million in 2024, mainly tied to Astellas and Ipsen collaborations.
Net loss was $191.1 million, or $22.49 per share, versus $227.5 million, or $29.40 per share, in 2024.
Restructuring and related costs were $53.4 million in 2025, compared with none in 2024.
Cash, cash equivalents and marketable securities were $141.4 million at December 31, 2025, versus $316.9 million a year earlier.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.